Nonfatal PML in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate

Neurology: Neuroimmunology and NeuroInflammation - United States
doi 10.1212/nxi.0000000000000274
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis

Prescriber
Pharmacology
2014English

B-Cell Composition in the Blood and Cerebrospinal Fluid of Multiple Sclerosis Patients Treated With Dimethyl Fumarate

Multiple Sclerosis and Related Disorders
MedicineNeurology
2018English

HDL-cholesterol Elevation Associated With Fingolimod and Dimethyl Fumarate Therapies in Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Cryptococcal Meningoencephalitis Treated With Fingolimod in a Patient With Multiple Sclerosis

Turkiye Klinikleri Journal of Case Reports
2019English

Dimethyl Fumarate in the Management of Multiple Sclerosis: Appropriate Patient Selection and Special Considerations

Therapeutics and Clinical Risk Management
2016English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Dimethyl Fumarate Treatment Alters NK Cell Function in Multiple Sclerosis

European Journal of Immunology
AllergyImmunology
2017English

Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod

JAMA Neurology
Neurology
2016English

A Retrospective Analysis of Real-World Discontinuation Rates With Delayed-Release Dimethyl Fumarate in Patients With Relapsing–Remitting Multiple Sclerosis

Neurology and Therapy
Neurology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy